Foto del docente

Giovanni Martinelli

Professore associato confermato

Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale

Settore scientifico disciplinare: MED/15 MALATTIE DEL SANGUE

Pubblicazioni

vai alle Pubblicazioni

Pubblicazioni antecedenti il 2004

Pubblicazioni del Prof. Giovanni Martinelli nel 2010 su riviste. 
1. Follo et al. Synergistic induction of PI-PLCβ1 signaling by azacitidine and valproic acid in high-risk myelodysplastic syndromes. Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, UK (2010).  
2. Kantarjian et al. Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase following imatinib resistance or intolerance: 24-month follow-up results. Blood (2010).
3. Della Peruta et al. Protein tyrosine phosphatase receptor type {gamma} is a functional tumor suppressor gene specifically downregulated in chronic myeloid leukemia. Cancer Research (2010) vol. 70 (21) pp. 8896-906
4. Lo-Coco et al. Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: results of the AIDA-2000 trial of the GIMEMA Group. Blood (2010) vol. 116 (17) pp. 3171-9.   
5. Soverini et al. IDH2 somatic mutations in chronic myeloid leukemia patients in blast crisis. Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, UK (2010).  
6. Iacobucci et al. The PAX5 gene is frequently rearranged in BCR-ABL1-positive acute lymphoblastic leukemia but is not associated with outcome. A report on behalf of the GIMEMA Acute Leukemia Working Party. Haematologica (2010) vol. 95 (10) pp. 1683-90    7. Baldazzi et al. B-cell acute lymphoblastic leukemia as evolution of a 8p11 myeloproliferative syndrome with t(8;22)(p11;q11) and BCR-FGFR1 fusion gene. Leuk Res (2010) vol. 34 (10) pp. e282-5.   
8. Papayannidis et al. Philadelphia positive (Ph+) acute lymphoblastic leukemia (ALL) patient with breast infiltration. Leuk Res (2010) vol. 34 (9) pp. e246-7.    9. Castagnetti et al. Deletions of the derivative chromosome 9 do not influence the response and the outcome of chronic myeloid leukemia in early chronic phase treated with imatinib mesylate: GIMEMA CML Working Party analysis. J Clin Oncol (2010) vol. 28 (16) pp. 2748-54.   
10. Mancini et al. mTOR inhibitor RAD001 (Everolimus) enhances the effects of imatinib in chronic myeloid leukemia by raising the nuclear expression of c-ABL protein. Leuk Res (2010) vol. 34 (5) pp. 641-8.   
11. Lilly et al. Dasatinib 140 mg once daily versus 70 mg twice daily in patients with Ph-positive acute lymphoblastic leukemia who failed imatinib: Results from a phase 3 study. Am J Hematol (2010) vol. 85 (3) pp. 164-70